Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety von Mahlangu, Johnny, Levy, Howard, Kosinova, Marina V., Khachatryan, Heghine, Korczowski, Bartosz, Makhaldiani, Levani, Iosava, Genadi, Lee, Martin, Del Greco, Frank

Volltext

Serpin-PC in Persons with Severe Hemophilia (PwH): Updated Results from a Multicenter Multi-Part, First-in-Human Study von Baglin, Trevor, Huntington, James A., Koch, Annelize, Mocanu, Irina, Makhaldiani, Levani

Volltext

Serpinpc in Persons with Severe Hemophilia (PwH): Updated Results from a Multi-Center, Multi-Part, First-in-Human Study von Baglin, Trevor, Koch, Annelize, Mocanu, Irina, Makhaldiani, Levani, Huntington, James A.

Volltext

Phase 2/3 Trial of Subcutaneously Administered Marzeptacog Alfa (activated) an Engineered FVIIa in Hemophilia with Inhibitors - Pharmacokinetics, Pharmacodynamics, Safety and Effic... von Levy, Howard, Makhaldiani, Levani, Iosava, Genadi, Mahlangu, Johnny, Kosinova, Marina V, Khacchatryan, Heghine, Del Greco, Frank, Booth, Frank V. McL

Volltext